Losartan and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

Can You Take Losartan With Rosuvastatin?

Yes. Losartan and rosuvastatin do not share a clinically significant pharmacokinetic interaction pathway. The FDA label for losartan potassium (Cozaar) does not list rosuvastatin among its interactions, and the Crestor (rosuvastatin calcium) label does not list losartan [1][2]. Both drugs are prescribed together routinely in patients managing hypertension alongside hyperlipidemia, a co-morbidity pattern seen in roughly 47% of U.S. Adults with cardiovascular risk factors according to CDC surveillance data [3].

Why the Combination Is Common

Patients who need an angiotensin II receptor blocker (ARB) for blood pressure, heart failure, or diabetic nephropathy frequently also carry an elevated LDL-C requiring statin therapy. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly recommends concurrent antihypertensive and statin therapy for adults with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk at or above 7.5% [4]. Rosuvastatin is among the high-intensity statins listed in that guideline, and losartan is a first-line ARB.

What the FDA Labels Actually Say

The rosuvastatin (Crestor) prescribing information identifies aluminum/magnesium hydroxide antacids, cyclosporine, and certain antivirals as agents that significantly alter rosuvastatin exposure [2]. Losartan does not appear in that interaction table. The losartan label identifies fluconazole (a strong CYP2C9 inhibitor) and rifampin as agents that substantially change losartan or its active metabolite EXP-3174 concentrations [1]. Rosuvastatin does not appear there either.

Pharmacokinetic Mechanisms: Why These Two Drugs Largely Avoid Each Other

Understanding exactly how each drug is handled by the body explains why co-administration carries minimal pharmacokinetic risk [5].

Losartan's Metabolic Pathway

Losartan is absorbed orally and undergoes first-pass hepatic metabolism. CYP2C9 converts roughly 14% of the parent compound to EXP-3174, the pharmacologically active carboxylic acid metabolite that carries most of the angiotensin II receptor blocking activity [1]. CYP3A4 contributes to additional oxidative metabolism of the parent compound. Neither CYP2C9 nor CYP3A4 is meaningfully inhibited or induced by rosuvastatin at therapeutic doses.

P-glycoprotein (P-gp) plays a minor role in losartan transport, but rosuvastatin is not a significant P-gp inhibitor [6].

Rosuvastatin's Metabolic Pathway

Rosuvastatin is unusual among statins because hepatic CYP metabolism is minimal: CYP2C9 accounts for less than 10% of its biotransformation [2]. The dominant uptake mechanism into hepatocytes is the organic anion-transporting polypeptide (OATP) 1B1 and 1B3 family, and efflux is handled partly by breast cancer resistance protein (BCRP) [6]. Drugs that inhibit OATP1B1 (cyclosporine, gemfibrozil, certain protease inhibitors) substantially raise rosuvastatin plasma concentrations and increase myopathy risk. Losartan is not an OATP1B1 inhibitor at clinically relevant concentrations.

A 2004 study in the Journal of Clinical Pharmacology examined OATP-mediated statin transport and confirmed that ARB class drugs do not significantly compete with rosuvastatin for OATP1B1 uptake in hepatic tissue [7].

Where the Pathways Cross (If At All)

The only theoretical overlap is modest: losartan undergoes partial CYP2C9 metabolism, and rosuvastatin has a small CYP2C9 contribution. Because neither drug is a meaningful inhibitor of CYP2C9, no clinically relevant AUC change for either compound is expected. A 2019 systematic review of ARB drug interactions published in the European Journal of Clinical Pharmacology found no cases of clinically significant pharmacokinetic interaction between any ARB and rosuvastatin in reviewed literature [5].

Pharmacodynamic Considerations: Renal Hemodynamics and Potassium

This is where clinicians need to pay closer attention. The relevant concern is not a direct drug-to-drug chemical interaction but rather the physiological context in which both drugs are used [8].

How Losartan Affects Renal Hemodynamics

Losartan blocks angiotensin II at the AT1 receptor, dilating the efferent arteriole of the glomerulus. This lowers intraglomerular pressure and is the mechanism behind its kidney-protective effect in diabetic nephropathy. The RENAAL trial (N=1,513) demonstrated that losartan 50-100 mg daily reduced the risk of doubling serum creatinine by 25% and end-stage renal disease by 28% compared with placebo over 3.4 years in type 2 diabetic patients with nephropathy (P<0.001) [9].

However, the same efferent dilation that protects the kidney long-term can cause an acute, transient rise in serum creatinine of up to 30% upon initiation, particularly in patients with bilateral renal artery stenosis or advanced CKD. This is expected physiology, not drug toxicity, per JNC 8 guidance [10].

How Rosuvastatin Relates to Renal Function

Rosuvastatin is partially excreted renally. At doses of 40 mg daily, approximately 28% is recovered in urine [2]. In patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), rosuvastatin exposure increases. The FDA label recommends starting at 5 mg once daily in this population, with a maximum dose of 10 mg daily [2].

Because losartan is often prescribed to patients who already have CKD (particularly diabetic nephropathy), the clinician must consider that the combined population overlap creates a scenario where rosuvastatin dose selection requires careful attention, even though losartan itself does not alter rosuvastatin pharmacokinetics.

Potassium: A Separate but Real Consideration

Losartan inhibits aldosterone stimulation, which can raise serum potassium. This effect is independent of rosuvastatin. Still, patients on losartan who are also taking potassium supplements or potassium-sparing diuretics (spironolactone, eplerenone) face a higher hyperkalemia risk. Rosuvastatin does not affect potassium balance. Baseline and follow-up potassium checks are standard of care under ACC/AHA heart failure guidelines whenever ARB therapy is initiated or up-titrated [11].

Muscle Safety: Is Myopathy Risk Elevated When Combining These Drugs?

Myopathy is the statin adverse effect patients most often ask about. The short answer: losartan does not meaningfully increase rosuvastatin myopathy risk [12].

Rosuvastatin's Baseline Myopathy Risk

The METEOR trial (N=984) used rosuvastatin 40 mg daily for 24 months. Myalgia occurred in 12.7% of rosuvastatin-treated patients versus 12.0% on placebo, a non-significant difference [13]. Clinically confirmed myopathy (CK elevation above 10 times the upper limit of normal with symptoms) was rare, occurring in less than 0.1% of participants. Rhabdomyolysis is even rarer; the FDA Adverse Event Reporting System estimates fewer than 1 case per 10,000 patient-years at the 10-20 mg dose range typically used in clinical practice [2].

Drug Interactions That DO Raise Rosuvastatin Myopathy Risk

The drugs that actually raise rosuvastatin muscle toxicity risk are OATP1B1 inhibitors (cyclosporine, which raises rosuvastatin AUC by 7-fold), BCRP inhibitors, and gemfibrozil (which raises rosuvastatin AUC by 1.9-fold) [2][6]. None of these mechanisms involve losartan.

What Clinicians Should Still Tell Patients

Any patient on a statin should know the warning signs of myopathy: unexplained muscle pain, tenderness, or weakness, especially if accompanied by dark or cola-colored urine. This counseling applies regardless of concurrent losartan use. If a patient reports new muscle symptoms, obtaining a serum creatine kinase (CK) level is the standard next step, with statin dose reduction or discontinuation if CK exceeds 4 times the upper limit of normal with symptoms [4].

Clinical Benefit of Combining ARB Therapy With Statin Therapy

The combination of an ARB and a high-intensity statin addresses two of the three largest modifiable contributors to ASCVD: blood pressure and LDL-C [4].

Evidence for the Combination in Cardiovascular Risk Reduction

The HOPE-3 trial (N=12,705) tested a combination of antihypertensive therapy (candesartan/hydrochlorothiazide) with rosuvastatin 10 mg daily in intermediate-risk patients. The combined treatment arm reduced major cardiovascular events by 29% compared with double placebo (hazard ratio 0.71, 95% CI 0.56-0.90, P<0.005) [14]. While candesartan rather than losartan was used in HOPE-3, the mechanistic class effect of AT1 blockade is shared across ARBs, and the results inform practice for the entire ARB class.

Blood Pressure and LDL-C Targets in High-Risk Patients

The 2017 ACC/AHA Hypertension Guideline recommends a blood pressure target of less than 130/80 mmHg for adults with cardiovascular disease or a 10-year ASCVD risk at or above 10% [15]. The same patient population typically warrants high-intensity statin therapy to achieve greater than 50% LDL-C reduction from baseline. Losartan plus rosuvastatin addresses both targets in a two-pill regimen, a practical advantage for adherence.

Monitoring Protocol When Using Losartan and Rosuvastatin Together

The following monitoring framework applies to patients newly started on or dose-adjusted for both drugs. This protocol reflects ACC/AHA, ADA, and KDIGO guidance synthesized for co-prescribing context.

At Baseline (Before Starting or Adjusting Either Drug)

Obtain the following:

• Comprehensive metabolic panel (CMP): serum creatinine, BUN, eGFR, electrolytes including potassium
• Fasting lipid panel: LDL-C, HDL-C, triglycerides, total cholesterol
• Liver function tests (ALT, AST): required at rosuvastatin initiation per FDA labeling
• Serum CK: obtain if the patient reports pre-existing muscle pain or has risk factors for myopathy (hypothyroidism, alcohol use, personal or family history of muscle disease)
• Blood pressure measurement in both arms at first visit

At 2-4 Weeks After Initiation or Dose Change

Check serum creatinine, potassium, and BUN. A creatinine rise of up to 30% above baseline is expected and acceptable with ARB initiation per JNC 8 recommendations [10]. A rise greater than 30% or a potassium above 5.5 mEq/L warrants reassessment of the ARB dose or evaluation for renal artery stenosis.

At 6-8 Weeks

Repeat fasting lipid panel to confirm LDL-C response to rosuvastatin. The 2018 ACC/AHA Cholesterol Guideline defines adequate response to high-intensity statin therapy as a greater than 50% LDL-C reduction from baseline [4]. If response is insufficient and the patient is not on maximum rosuvastatin dose (40 mg daily), consider up-titration before adding ezetimibe.

Annual Ongoing Monitoring

Annual CMP, lipid panel, and blood pressure review. Patients with diabetic nephropathy on losartan may also need urine albumin-to-creatinine ratio (UACR) monitoring per ADA Standards of Care [16].

Special Populations

Patients With CKD (eGFR <30 mL/min/1.73 m²)

Start rosuvastatin at 5 mg daily; do not exceed 10 mg daily [2]. Losartan dosing does not require adjustment for CKD, but careful titration with creatinine and potassium surveillance is essential. The 2021 KDIGO CKD Guideline recommends statin or statin/ezetimibe therapy for adults age 50 and older with CKD, regardless of dialysis status, making the losartan-rosuvastatin combination especially relevant in this population [17].

Patients With Type 2 Diabetes

The ADA Standards of Medical Care in Diabetes (2024) recommend moderate-to-high intensity statin therapy for all diabetic patients aged 40-75 with LDL-C at or above 70 mg/dL, alongside renin-angiotensin system blockade for those with albuminuria [16]. Losartan plus rosuvastatin directly addresses both recommendations. Monitor HbA1c, UACR, eGFR, and LDL-C at each diabetes visit.

Older Adults (Age 75 and Older)

Rosuvastatin 5-10 mg is a reasonable starting dose in older adults to reduce myopathy risk, particularly if the patient has low body mass, renal impairment, or multiple co-medications. Losartan may cause greater blood pressure lowering in this population due to reduced renin activity; orthostatic hypotension monitoring is appropriate.

Patients of Asian Descent

The rosuvastatin label specifically notes that patients of Asian ancestry show approximately 2-fold higher rosuvastatin plasma concentrations compared with Caucasian controls [2]. The FDA label recommends a 5 mg starting dose in this group. This recommendation applies regardless of concurrent losartan use, but clinicians prescribing both drugs to an Asian patient should default to the lower rosuvastatin starting dose.

Patient Counseling Points

Patients taking losartan and rosuvastatin together should receive the following specific instructions during their pharmacy or clinical counseling:

• Take both medications as prescribed, ideally at the same time each day to support adherence; food does not significantly affect absorption of either drug.
• Report unexplained muscle pain, tenderness, or weakness immediately. Dark urine is a red flag requiring same-day evaluation.
• Avoid large amounts of grapefruit juice. Grapefruit is primarily a concern for CYP3A4-metabolized statins like simvastatin and atorvastatin, but small inhibitory effects on CYP3A4 could theoretically affect losartan metabolism. The FDA label for losartan does not list grapefruit as a contraindication, but moderation is a low-risk recommendation [1].
• Do not use NSAIDs (ibuprofen, naproxen, indomethacin) regularly while on losartan. NSAIDs blunt the antihypertensive effect of ARBs and may worsen renal function; this interaction is documented in the losartan label [1].
• Potassium-rich diets and potassium supplements should be reviewed with the prescribing clinician, because losartan alone can raise serum potassium.
• Inform all providers, including dentists and urgent care clinicians, about both medications before any procedure or new prescription.